Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,307.20 -80.41 -0.52%
S&P 500 1,655.35 -13.81 -0.83%
Nasdaq 3,463.30 -38.82 -1.11%
Ticker Volume Price Price Delta
STOXX 50 2,760.17 -74.84 -2.64%
FTSE 100 6,700.70 -139.57 -2.04%
DAX 8,296.04 -234.85 -2.75%
Ticker Volume Price Price Delta
Nikkei 14,484.00 -1,143.28 -7.32%
Hang Seng 22,669.70 -591.40 -2.54%
S&P/ASX 200 5,062.45 -102.92 -1.99%
  • Exchange: NASDAQ GM
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

ARQL:US

2.7100 USD 0.0700 2.52%

As of 20:10:00 ET on 05/22/2013.

Company Profile for Arqule Inc (ARQL)

ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.

Contact Information

Arqule Inc

19 Presidential Way
Woburn, MA 01801-5140
United States
Phone: 1-781-994-0300
Fax: 1-781-376-6019

Key Executives for Arqule Inc (ARQL)

Paolo PucciChief Executive OfficerPeter S LawrencePresident/COO/Secy/Gen Cnsl
Brian SchwartzSenior VP/Chief Medical OfcrThomas C K ChanSenior VP/Chf Scientific Ofcr
William B BoniVP:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil